28-30 January 2019
Paris, France
4 Passes Remaining. Book Now!

Day One
Tuesday 29 January 2019

Day Two
Wednesday 30 January 2019

07.20
Morning Coffee & Registration

08.20
Chairperson Opening Remarks

Moving to Mechanism – A New Focus on Establishing Disease Causation

08.30
Definition of a Healthy Microbiome and if Disturbed – How to Shape It Back to Normal

  • Pr Lars Engstrand Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet

09.00
Identification of Microbiome-Based Biomarkers and Challenges Associated with Their Application: Case Studies from Obesity, IBD, and Cancer

  • Julia Cope Director of Scientific Operations, Diversigen

09.30
Investigating the Causal Role of the Microbiota in Immune- Mediated Diseases

10.00
Shotgun Sequencing & Strain-Level Analysis: Study Design for Pre-Clinical & Clinical Development

10.30
Speed Networking

11.00
Morning Refreshments



 Live Biotherapeutic Identification & Development (Single Strain & Consortia)



 

11.30 Precision Metagenomics Microbiome Analysis in Personalised Medicine

Trevor Lawley, Chief Scientific Officer, Microbiotica

11.50 Functional Analysis of Microbial Communities for Novel LBP Discovery

Daniel van der Lelie, Chief Scientific Officer, Gusto Global

12.10 Standardising Microbiomics – Removing Bias in Collection, Purification and Analyses

Thomas Kuri, Scientific Director, Zymo Research

12.20 A Preclinical Assessment of a Rationally Designed LBP

Ling-Yang Hao, Principal Scientist, Janssen Pharmaceuticals

12.40 Delivery, Survival, Engraftment & Activity of LBPs in the Gastrointestinal Tract

Massimo Marzorati, Chief Executive Officer, ProDigest



13.10 Lunch & Networking



 

 Small Molecule Identification & Development

 



 

14.10 Microbial Metabolites as Potential ImmunoModulators

Jim Brown, Director of Computational Biology & Senior Fellow, GSK

14.30 Identifying Bacterial-Derived Metabolites and Small Molecules for Metabolic Disease & Obesity

Gregory Lambert, CEO & VP, R&D, TarEDys



 Pre-Clinical Predicting – Modelling for Microbiome-Based Therapeutics



 

14.50 How Much Do We Know about the Human Gut Microbiome?

Alexandre Almeida, Postdoctoral Research Fellow, European Bioinformatics Institute



 Pharmaceutical Perspectives & Partnership Strategies for Microbiome-Based Therapeutics



 

15.10 The Value and Meaning of Partnerships in the Microbiome Space

Ken Blount, Chief Scientific Officer, Rebiotix



 CMC/Manufacturing & Scale-Up of Microbiome-Based Therapeutics



 

11.30 Development of Oral Live Bio-Therapeutic Products – a CDMOs Perspective

Ryan Wilson, Head of Live-Bio Programmes, Quay Pharma

12.00 Scale up and GMP Manufacture of Live Biotherapeutic Products

Tina Christensen Ram, Head of Quality, Luina Bio



 FMT Clinical Design & Development



 

12.10 Faecal Microbiota Transplantation (FMT): regulation, commercialisation and future perspectives

James McIlroy, Founder & Chief Business Officer, EnteroBiotix

12.30 FFMT-Based Discovery: From Platform to Product

Luc Sterkman, Chief Executive Officer, Caelus Health



12.50 Lunch & Networking



 

14.10 Making the Difference in LBP Drug Development and Manufacturing

Adrien Nivoliez, Chief Executive Officer, Biose industrie

14.20 Investigating the Human Microbiome in GVHD/GVL

Pr Mohamed Mohty MD, Professor of Hematology and Head of Hematology Department, Saint-Antoine Hospital and University Pierre & Marie Curie




Clinical Trial Design & Development – Early & Late Stage Development

 



 

14.40 Developing a New Generation of First-In-Class High Diversity Microbiome Biotherapeutics to Treat Life-Threatening Diseases

Herve Affagard, Chief Executive Officer, MaaT Pharma

15.00 Genome Based Comparison and Interpretation for the Development of Microbiome-Based Therapeutic Products

Herwig Bachmann, Expertise Group Leader, NIZO

15.30
Afternoon Refreshments & Networking

16.00 Microbiome Alliances at Ferring Pharmaceuticals

Kristin Wannerberger, Director R&D Alliance Management, Ferring Pharmaceuticals

16.20 Panel Discussion: New Perspectives on Pharma & Biotech Partnerships in the Microbiome

Jessica Schneider, Associate Scientific Director, Takeda

Kristin Wannerberger, Director of Partnerships, Ferring Pharmaceuticals

Mike Romanos, Chief Executive Officer, Microbiotica

16.00 Rollercoaster Ride for the Pioneers in Microbiome Clinical Programme Development

Ken Blount, Chief Scientific Officer, Rebiotix

16.20 Studying Microbiome-Host Interactions to Translate Microbiome Drugs into the Clinic

David Cook, Chief Scientific Officer, Seres Therapeutics

16.40 Clinical Considerations of Rationally Designed Live Bacterial Cocktails

Bruce Roberts, Chief Scientific Officer, Vedanta Biosciences

Innovation Power Hour: Start-Up Showcase

17.10
Establishing the Role of Biofilms in Human Microbiome Discovery

17.30
Novel Therapeutic Approaches Targeting the Microbiome in Metabolic Diseases

17.50
Pioneering the Microbiome Oral Delivery for First-in-Man Studies

18.20
Chairperson Closing Remarks

18.30
Close of Conference Day One and Evening Drinks Reception Hosted by the Microbiome Movement